131 related articles for article (PubMed ID: 30306600)
1. Optimizing and evaluating biomarker combinations as trial-level general surrogates.
Gabriel EE; Sachs MC; Daniels MJ; Halloran ME
Stat Med; 2019 Mar; 38(7):1135-1146. PubMed ID: 30306600
[TBL] [Abstract][Full Text] [Related]
2. Comparing biomarkers as trial level general surrogates.
Gabriel EE; Daniels MJ; Halloran ME
Biometrics; 2016 Dec; 72(4):1046-1054. PubMed ID: 27038302
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K; Maclehose H; Bergman H; Ben-Aharon I; Nagpal S; Goldberg E; Pitan F; Cunliffe N
Cochrane Database Syst Rev; 2012 Nov; 11():CD008521. PubMed ID: 23152260
[TBL] [Abstract][Full Text] [Related]
4. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K; Maclehose H; Bergman H; Ben-Aharon I; Nagpal S; Goldberg E; Pitan F; Cunliffe N
Cochrane Database Syst Rev; 2012 Feb; (2):CD008521. PubMed ID: 22336845
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and comparison of predictive individual-level general surrogates.
Gabriel EE; Sachs MC; Halloran ME
Biostatistics; 2018 Jul; 19(3):307-324. PubMed ID: 28968890
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
7. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine.
Goveia MG; Ciarlet M; Owen KE; Ranucci CS
Ann N Y Acad Sci; 2011 Mar; 1222():14-8. PubMed ID: 21434938
[TBL] [Abstract][Full Text] [Related]
8. Predictive cluster level surrogacy in the presence of interference.
Gabriel EE; Follmann DA
Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
[TBL] [Abstract][Full Text] [Related]
9. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
Li Y; Taylor JM; Elliott MR; Sargent DJ
Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
[TBL] [Abstract][Full Text] [Related]
10. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
11. Flexible evaluation of surrogacy in platform studies.
Sachs MC; Gabriel EE; Crippa A; Daniels MJ
Biostatistics; 2023 Dec; 25(1):220-236. PubMed ID: 36610075
[TBL] [Abstract][Full Text] [Related]
12. Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalisations in Brazil.
El Khoury AC; Mast TC; Ciarlet M; Markson L; Goveia MG; Munford V; Rácz ML
Mem Inst Oswaldo Cruz; 2011 Aug; 106(5):541-5. PubMed ID: 21894373
[TBL] [Abstract][Full Text] [Related]
13. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.
Giaquinto C; Dominiak-Felden G; Van Damme P; Myint TT; Maldonado YA; Spoulou V; Mast TC; Staat MA
Hum Vaccin; 2011 Jul; 7(7):734-48. PubMed ID: 21734466
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
Pediatrics; 2010 Feb; 125(2):e208-13. PubMed ID: 20100757
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
[TBL] [Abstract][Full Text] [Related]
16. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua.
Patel M; Pedreira C; De Oliveira LH; Tate J; Orozco M; Mercado J; Gonzalez A; Malespin O; Amador JJ; Umaña J; Balmaseda A; Perez MC; Gentsch J; Kerin T; Hull J; Mijatovic S; Andrus J; Parashar U
JAMA; 2009 Jun; 301(21):2243-51. PubMed ID: 19491186
[TBL] [Abstract][Full Text] [Related]
17. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.
Vesikari T; Karvonen A; Ferrante SA; Kuter BJ; Ciarlet M
Pediatr Infect Dis J; 2010 Oct; 29(10):957-63. PubMed ID: 20442684
[TBL] [Abstract][Full Text] [Related]
18. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants.
Shui IM; Baggs J; Patel M; Parashar UD; Rett M; Belongia EA; Hambidge SJ; Glanz JM; Klein NP; Weintraub E
JAMA; 2012 Feb; 307(6):598-604. PubMed ID: 22318281
[TBL] [Abstract][Full Text] [Related]
19. Addition of history of intussusception as a contraindication for rotavirus vaccination.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(41):1427. PubMed ID: 22012117
[TBL] [Abstract][Full Text] [Related]
20. An ensemble approach to predicting the impact of vaccination on rotavirus disease in Niger.
Park J; Goldstein J; Haran M; Ferrari M
Vaccine; 2017 Oct; 35(43):5835-5841. PubMed ID: 28941619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
